Trevi Therapeutics, Inc. Elects James V. Cassella as a Class I Director
February 18, 2020 at 04:18 pm
Share
On February 13, 2020, the Board of Directors of Trevi Therapeutics, Inc. elected James V. Cassella, Ph.D. to the Board as a Class I Director, effective immediately, with a term expiring at the 2020 annual meeting of stockholders. Dr. Cassella joins Trevi’s Board with over 30 years of drug development experience working with emerging growth biopharmaceutical companies. He has served as Chief Development Officer of Concert Pharmaceuticals since 2015, and prior to that held senior executive and leadership roles with Alexza Pharmaceuticals, Inc. and Neurogen Corporation. Before joining the biopharmaceutical industry, Dr. Cassella was Assistant Professor of Neurosciences at Oberlin College.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.